查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1994187

生物製藥外包市場：2026-2032年全球市場預測（依服務類型、治療領域、製程階段、最終用戶及外包模式分類）

Biologics Outsourcing Market by Service Type, Therapeutic Area, Process Stage, End User, Outsourcing Model - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，生物製藥外包市場價值將達到 255.1 億美元，到 2026 年將成長至 284.5 億美元，到 2032 年將達到 594.5 億美元，複合年成長率為 12.84%。

主要市場統計數據
基準年 2025 255.1億美元
預計年份：2026年 284.5億美元
預測年份 2032 594.5億美元
複合年成長率 (%) 12.84%

一個全面的策略框架，定義了生物製劑外包在加速開發進度和降低複雜治療專案風險方面不斷變化的作用。

對於尋求加速研發進度、管理資本投資並獲取專業能力的企業而言，生物製藥外包已成為一項策略要務。過去十年，治療方法的日益複雜化和先進治療方法的湧現，提升了外部合作夥伴的作用，使外包從單純的成本管理工具轉變為研發和商業化策略的核心要素。因此，研發和生產企業都在重新評估其合作夥伴關係，以確保產能、降低技術風險，並充分利用分析、填充和夥伴關係以及上游和下游生產等領域的專業知識。

生物製藥外包價值鏈重組的多方面概述，包括技術進步、監管變化和商業重組。

生物製藥外包格局正經歷著一場多方面的變革，這場變革是由技術、監管和商業因素共同驅動的。一次性技術和模組化設施設計的創新，縮短了前置作業時間，並實現了靈活的產能部署；而先進的分析技術和數位化平台，則加深了對製程的理解，並加速了技術轉移。同時，細胞和基因療法的興起，催生了對專業載體生產、封閉式系統處理和客製化分析檢測的需求，從而重塑了供應商的能力和夥伴關係模式。

對近期美國關稅調整如何影響生物製藥外包的供應鏈經濟、生產力計畫和風險緩解策略進行實證評估。

2025年美國關稅政策調整和貿易措施的累積影響為生物製藥供應鏈帶來了新的考量因素，影響採購、資本規劃和區域籌資策略。具體而言，關稅的提高和進口零件分類範圍的擴大增加了關鍵投入品（例如一次性組件、層析法介質、專用過濾設備和分析儀器）的到貨成本。因此，製造商和服務供應商不得不重新評估其供應商合約和總擁有成本 (TCO) 的計算，以維持利潤率和專案進度。

詳細的細分分析，將服務類型、治療方式、流程階段、外包模式和最終用戶優先順序與策略能力要求相匹配。

透過對生物製藥外包市場進行細分，供應商和買家可以清楚地確定應重點關注的策略領域。分析服務、研發活動、灌裝和表面處理工程以及生產製造等服務類型構成不同的價值流，各自具有不同的風險狀況和基礎設施需求。在生產製造領域，下游和上游工程所需的技能和資本投入也各不相同。下游製程著重於層析法和過濾能力，需要高分析精度和穩定的耗材供應；而上游工程分為可快速切換的一次性系統和適用於大批量生產的耐用不​​銹鋼平台。

對美洲、歐洲、中東和非洲以及亞太地區的需求、製造能力、監管趨勢和投資趨勢進行綜合區域分析。

區域趨勢對供應商能力、監管協調和投資流動有顯著影響。在美洲，生物技術創新高度集中，擁有健全的創業融資生態系統和完善的監管管道，因此對早期研發服務和商業化生產規模化生產的需求都非常旺盛。該地區在專業供應商網路、經驗豐富的監管審查人員以及接近性大規模患者群體等方面具有優勢，這些優勢共同促進了專案的快速推進和高效的供應鏈協調。

基於實證的企業策略模式：揭示主要供應商如何透過調整產能、專業化、數位化投資和夥伴關係模式，在生物製劑外包市場中佔據領先地位

生物製劑外包生態系統中的主要企業正在尋求差異化策略，以平衡產能提升、技術專長和商業性夥伴關係，從而抓住新的機會。一些供應商專注於垂直整合，建構從分析開發到商業填充和包裝的全流程能力，提供端到端解決方案，減少流程間的交接，縮短產品上市時間。另一些供應商則專注於病毒載體生產、高通量分析或連續下游製程等細分領域，承接高度複雜的項目，憑藉深厚的專業知識和檢驗的製程流程，在競爭中佔據優勢地位。

為高階主管提供可操作且優先的行動方案，以投資於自身能力，從而加強供應鏈、加速技術轉讓，並實現可衡量的韌性和競爭優勢。

行業領導者應採取切實可行且具有前瞻性的措施來增強競爭力並業務永續營運。首先，他們應仔細梳理供應鏈，識別單點故障、關稅風險和關鍵前置作業時間依賴性，然後實施分階段的風險緩解計劃，該計劃應結合戰略庫存、供應商多元化和替代零件認證流程。其次，他們應保留部分不銹鋼設備產能，用於高產量、低成本的生產，同時優先投資於模組化和一次性技術，因為這些技術的柔軟性能夠帶來可衡量的效益。

採用高度透明的混合方法研究途徑，結合一手訪談、第二手資料、細分映射和情境分析，得出可操作的見解。

本研究採用混合方法，確保研究結果的穩健性和實用性。主要研究包括對研發和製造企業的管理人員和技術負責人進行結構化訪談，並輔以與監管和供應鏈專家的諮詢，以檢驗假設並了解實際決策的啟發式方法。這些主要資訊與來自科學文獻、監管指導文件、行業白皮書和檢驗的公開資訊的有針對性的二手研究進行交叉比對，從而構建了一個全面的證據基礎。

簡要概述了買方和供應商在策略上面臨的挑戰，即如何調整自身能力、管治和投資，以實現永續的生物製藥發展。

生物製藥外包的趨勢反映了該行業當前的策略轉型狀態。技術創新、不斷變化的監管環境以及供應鏈重組都增加了合作夥伴選擇和專案實施的難度。那些積極調整籌資策略、投資特定能力並建立數據驅動決策框架的組織，將更有能力將科學進步轉化為可靠且擴充性的治療方法。同時，貿易政策的變化和區域投資動向也凸顯了建構敏捷供應鏈結構和進行充分情境規劃的必要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：生物製藥外包市場：依服務類型分類

  • 分析服務
  • 發展
  • 填充和精加工
  • 製造業
    • 下游
      • 層析法
      • 過濾
    • 上游
      • 一次使用
      • 不銹鋼

第9章：生物製藥外包市場：依治療領域分類

  • 細胞療法
    • 同種
    • 自體
  • 基因治療
    • 非病毒
    • 病毒載體
  • 單株抗體
  • 疫苗
    • 預防
      • 細菌
      • 病毒性的
    • 治療

第10章：以製程階段分類的生物製藥外包市場

  • 臨床
    • 第一階段
    • 第二階段
    • 第三階段
  • 商業的
  • 調查

第11章：生物製藥外包市場：以最終用戶分類

  • 生技公司
  • 製藥公司
  • 研究機構

第12章：以外包模式分類的生物製藥外包市場

  • CDMO
  • CMO
  • CRO

第13章：生物製藥外包市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：生物製藥外包市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：生物製藥外包市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國生物製藥外包市場

第17章：中國生物製藥外包市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AGC Biologics, Inc.
  • Almac Group Limited
  • BioReliance Corporation
  • Boehringer Ingelheim International GmbH
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • Cognate BioServices, Inc.
  • Eurofins Scientific SE
  • Evotec SE
  • Fujifilm Diosynth Biotechnologies, Inc.
  • ICON plc
  • IQVIA Holdings Inc.
  • KBI Biopharma, Inc.
  • Labcorp Drug Development, Inc.
  • Lonza Group AG
  • Medpace Holdings, Inc.
  • Parexel International Corporation
  • PPD, Inc.
  • PRA Health Sciences, Inc.
  • Recipharm AB
  • Samsung Biologics Co., Ltd.
  • Sartorius Stedim Biotech SA
  • Syngene International Limited
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec Co., Ltd.
Product Code: MRR-1A1A064C0467

The Biologics Outsourcing Market was valued at USD 25.51 billion in 2025 and is projected to grow to USD 28.45 billion in 2026, with a CAGR of 12.84%, reaching USD 59.45 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 25.51 billion
Estimated Year [2026] USD 28.45 billion
Forecast Year [2032] USD 59.45 billion
CAGR (%) 12.84%

Comprehensive strategic framing of biologics outsourcing that defines its evolving role in accelerating development timelines and de-risking complex therapeutic programs

Biologics outsourcing has become a strategic fulcrum for organizations seeking to accelerate development timelines, manage capital investment, and access specialized capabilities. Over the past decade, increasing therapeutic complexity and the emergence of advanced modalities have elevated the role of external partners, transforming outsourcing from a cost-management tactic into a core element of R&D and commercialization strategy. As a result, developers and manufacturers alike are recalibrating their partnerships to secure capacity, mitigate technical risk, and leverage expertise in areas such as analytics, fill-finish operations, and both upstream and downstream manufacturing.

This introduction situates outsourcing within a broader ecosystem shaped by technological innovation, evolving regulatory expectations, and shifting supply chain dynamics. Companies are balancing the need for agility with the imperative for quality and regulatory compliance, prompting a proliferation of specialized service providers and modular manufacturing approaches. In turn, buyers are increasingly selective, seeking partners who offer not only technical proficiency but also transparent risk management, traceability, and integrated digital capabilities. Consequently, outsourcing decisions now hinge on strategic alignment, long-term capacity planning, and the ability of partners to co-develop solutions that advance program timelines while protecting product integrity.

Moving forward, stakeholders must view outsourcing through a dual lens: as an operational necessity and as a strategic lever for competitive differentiation. Those who successfully integrate external expertise into tightly governed development and manufacturing pathways will be better positioned to capitalize on emerging opportunities across diverse therapeutic areas and process stages.

A multidimensional overview of technological advancements, regulatory evolution, and commercial realignments that are reshaping biologics outsourcing value chains

The biologics outsourcing landscape is undergoing a multipronged transformation driven by converging technological, regulatory, and commercial forces. Innovations in single-use technologies and modular facility design are enabling faster turnarounds and flexible capacity deployments, while advanced analytics and digital platforms are improving process understanding and accelerating tech transfer. Simultaneously, the rise of cell and gene therapies has created demand for specialized vector manufacturing, closed-system processing, and bespoke analytical testing, reshaping vendor capabilities and partnership models.

Regulatory frameworks are also evolving to accommodate novel modalities, prompting providers to invest in compliance expertise and documentation practices that streamline approvals. At the same time, commercial pressures, including the need for rapid scale-up, cost containment, and supply continuity, are incentivizing strategic consolidation and collaborations that combine development, clinical manufacturing, and commercial-scale capacities under integrated service models. These shifts are accompanied by a heightened emphasis on supply chain resilience, environmental sustainability, and workforce development, all of which influence sourcing decisions and capital allocation.

Consequently, market participants are redefining value propositions: providers that offer end-to-end solutions, demonstrate robust quality systems, and can adapt capacity to fluctuating demand are gaining advantage. Buyers are increasingly evaluating partners on the basis of technical depth, regulatory track record, and the ability to co-invest in process optimization and lifecycle support, making long-term strategic alignment a primary differentiator in a rapidly changing landscape.

An evidence-based assessment of how recent United States tariff adjustments have reshaped supply chain economics, capacity planning, and mitigation strategies across biologics outsourcing

The cumulative impact of tariff policy adjustments and trade measures in the United States in 2025 introduced new considerations for biologics supply chains, influencing procurement, capital planning, and regional sourcing strategies. In practical terms, increased duties and broader classification of imported components have elevated the landed cost of critical inputs such as single-use assemblies, chromatography media, specialized filtration equipment, and analytical instruments. As a result, manufacturers and service providers must reassess supplier contracts and total cost of ownership calculations to preserve margins and program timelines.

In response, stakeholders are pursuing a range of mitigation strategies. Some organizations are accelerating diversification of supplier bases to reduce exposure to tariff-affected trade corridors, while others are exploring local production or nearshoring options to stabilize input costs and shorten supply lead times. These adaptations often require upfront capital and operational adjustments, including qualification of alternative components, validation of new supply partners, and potential rework of manufacturing processes to ensure equivalence. Moreover, procurement teams are intensifying engagement with customs and trade specialists to optimize tariff classifications, leverage duty drawback mechanisms where applicable, and navigate regulatory compliance.

Beyond direct cost implications, tariff-driven shifts exert secondary effects on capacity planning and strategic partnerships. Providers facing increased import costs may delay or restructure expansion plans, impacting available capacity for clients. Conversely, incentives to localize production have catalyzed investments in regional manufacturing hubs, altering competitive dynamics. Ultimately, the interplay between trade policy and biologics outsourcing underscores the importance of scenario planning and agile supply chain design as essential components of commercial resilience.

In-depth segmentation analysis that maps service types, therapeutic modalities, process stages, outsourcing models, and end-user priorities to strategic capability requirements

A segmented view of the biologics outsourcing landscape clarifies where providers and buyers must concentrate strategic effort. When services are considered by type, analytical services, development activities, fill-finish operations, and manufacturing represent distinct value streams with different risk profiles and infrastructure needs. Within manufacturing, downstream and upstream activities require divergent skill sets and capital intensity; downstream processes focus on chromatography and filtration capabilities that demand high analytical rigor and consumable supply continuity, while upstream processes bifurcate between single-use systems that enable rapid changeover and stainless steel platforms that deliver durable, high-volume performance.

Therapeutic area segmentation further refines capability requirements. Cell therapy and gene therapy programs necessitate specialized handling, cold chain logistics, and vector production, with cell therapy split across allogeneic and autologous approaches that carry contrasting supply chain models and patient-specific complexities. Gene therapy distinctions between non-viral and viral vector strategies drive different manufacturing and analytical burdens. Monoclonal antibodies remain a foundational category demanding robust upstream and downstream scale-up expertise, while vaccines, both prophylactic and therapeutic, require antigen-specific manufacturing and regulatory approaches; prophylactic vaccines themselves span bacterial and viral indications, each with unique process considerations.

Process stage segmentation emphasizes that development, clinical, and commercial phases call for tailored outsourcing solutions. Clinical-stage work must accommodate Phase I through Phase III variability in scale and regulatory oversight, whereas commercial operations prioritize repeatability, cost efficiency, and supply security. Outsourcing models vary accordingly, with CDMOs, CMOs, and CROs offering differentiated scopes of service and capacity models. End users-biotech companies, pharmaceutical companies, and research institutes-approach outsourcing with distinct commercial and governance imperatives, shaping contract structures, risk allocation, and partnership duration expectations.

A regional intelligence synthesis that contrasts demand, manufacturing capacity, regulatory posture, and investment trends across the Americas, EMEA, and Asia-Pacific

Regional dynamics exert a powerful influence on provider capabilities, regulatory alignment, and investment flows. In the Americas, concentration of biotech innovation, robust venture funding ecosystems, and established regulatory pathways create strong demand for both early-stage development services and commercial manufacturing scale-up. This region benefits from a dense network of specialized providers, experienced regulatory reviewers, and proximity to large patient populations, which together facilitate faster program advancement and pragmatic supply chain coordination.

Europe, the Middle East and Africa exhibit a complex mix of advanced manufacturing hubs, progressive regulatory harmonization efforts, and variable market access conditions. European markets often lead in specialized contract manufacturing capacity, with a strong emphasis on high-quality GMP operations and an entrenched supplier base for analytical and downstream services. Meanwhile, pockets across the Middle East and Africa are attracting investment through incentive programs aimed at localizing biologics production, although infrastructure and skilled workforce development remain uneven.

Asia-Pacific has emerged as a pivotal region for capacity expansion, driven by rapidly growing domestic demand, competitive manufacturing costs, and government policies that encourage biomanufacturing investments. Markets across this region demonstrate significant capability in fill-finish and upstream operations, with an accelerating focus on higher-complexity modalities. Cross-regional partnerships and technology transfer initiatives are commonplace as companies seek to balance cost, scale, and access to regional markets, making Asia-Pacific a central node in global outsourcing strategies.

Evidence-based corporate strategic patterns revealing how leading providers are aligning capacity, specialization, digital investment, and partnership models to win in biologics outsourcing

Leading companies in the biologics outsourcing ecosystem are pursuing differentiated strategies that balance capacity expansion, technical specialization, and commercial partnerships to capture emerging opportunity. Some providers are concentrating on vertical integration, building capabilities that span analytical development through commercial fill-finish to offer end-to-end solutions that reduce handoffs and speed time to market. Others are specializing in niche areas such as viral vector production, high-throughput analytics, or continuous downstream processing to serve high-complexity programs where deep expertise and validated processes command premium positioning.

Mergers and strategic alliances remain key vectors for capability acquisition, allowing organizations to combine complementary strengths, enter new geographic markets, and accelerate service portfolios without the lead time required for organic expansion. Investment in digital twins, process analytical technology, and real-time monitoring is also a common theme, as companies seek to improve tech transfer success rates, reduce batch failures, and provide clients with transparent process data. In parallel, firms are sharpening commercial models to include risk-sharing elements, capacity reservations, and flexible pricing that align provider incentives with client program milestones.

Talent and quality systems continue to differentiate performance. Providers that demonstrate rigorous regulatory compliance, experienced clinical and technical teams, and scalable quality management frameworks are more successful in securing long-term partnerships. In sum, company strategies are evolving to emphasize resilience, deep technical differentiation, and client co-development as the primary drivers of sustainable growth.

Practical and prioritized actions for executives to fortify supply chains, accelerate tech transfer, and invest in capabilities that deliver measurable resilience and competitive advantage

Industry leaders should adopt a pragmatic and forward-looking set of actions to strengthen competitive position and operational resilience. First, map supply chains with granularity to identify single points of failure, tariff exposure, and critical lead-time dependencies, then implement tiered mitigation plans that combine strategic inventory, supplier diversification, and qualification pathways for alternate components. Second, prioritize investments in modular and single-use technologies where program flexibility yields measurable benefits, while maintaining selective stainless steel capabilities for high-volume, cost-effective production.

Third, deepen regulatory engagement early in development programs to accelerate approvals and reduce rework cycles; proactively align analytical strategies with regulatory expectations and invest in robust comparability datasets for process changes. Fourth, formalize partnerships that integrate development and manufacturing workflows, enabling smoother tech transfers and shared accountability for timelines and quality outcomes. Fifth, expand digital and analytics capabilities to enable real-time process monitoring, predictive maintenance, and enhanced process characterization, thereby reducing operational variability and improving yield.

Finally, build human capital pipelines through targeted training and cross-functional teams that blend scientific, regulatory, and supply chain expertise. By executing these actions in concert-balancing near-term risk mitigation with longer-term capability development-organizations can secure competitive advantage in a market that prizes speed, quality, and adaptability.

Transparent mixed-methods research approach integrating primary interviews, secondary evidence, segmentation mapping, and scenario analysis to produce actionable insights

This research leveraged a mixed-methods approach to ensure robustness and practical relevance. Primary research included structured interviews with executives and technical leaders from development and manufacturing organizations, complemented by consultations with regulatory experts and supply chain specialists to validate assumptions and capture real-world decision heuristics. These primary inputs were triangulated with targeted secondary research drawn from scientific literature, regulatory guidance documents, industry whitepapers, and validated public disclosures to build a comprehensive evidentiary base.

Analytical methods incorporated segmentation mapping to align capability requirements with therapeutic modality and process stage, as well as scenario analysis to explore the implications of trade policy changes, capacity constraints, and technology adoption pathways. Data synthesis emphasized reproducibility and transparency: methodological choices, inclusion criteria for primary sources, and validation steps were documented to enable auditability. Throughout, the research team applied conservative inference rules, avoided extrapolating beyond available evidence, and prioritized corroborated insights over speculative claims.

Limitations were acknowledged and addressed through sensitivity testing and by flagging areas of higher uncertainty where emerging technologies or policy shifts could materially change trajectories. The resulting methodology balances depth of technical insight with pragmatic applicability, producing findings designed to inform strategic planning and operational decision-making for stakeholders across the outsourcing continuum.

A concise synthesis that underscores the strategic imperatives for buyers and providers to align capabilities, governance, and investments for sustainable biologics development

The trajectory of biologics outsourcing reflects a sector in strategic transition: technological innovation, regulatory evolution, and supply chain realignment are collectively raising the bar for partner selection and program execution. Organizations that proactively reconfigure sourcing strategies, invest in targeted capabilities, and cultivate data-driven decision frameworks will be best positioned to translate scientific advances into reliable, scalable therapies. At the same time, trade policy developments and regional investment shifts underscore the need for agile supply chain architectures and informed scenario planning.

Success in this environment requires integrated thinking across scientific, operational, and commercial domains. Providers that combine deep technical expertise with transparent quality systems and flexible commercial models will capture comparative advantage, while buyers that partner strategically and share risks can accelerate time to clinic and market. Ultimately, the biologics outsourcing landscape rewards those who treat external partners as co-innovators and who invest in the governance, talent, and digital infrastructure necessary to sustain complex programs across the product lifecycle.

In closing, the imperative is clear: align outsourcing decisions with long-term strategic objectives, continuously reassess supplier and regional risk, and prioritize investments that deliver both immediate operational benefits and enduring capability uplift.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biologics Outsourcing Market, by Service Type

  • 8.1. Analytical Services
  • 8.2. Development
  • 8.3. Fill Finish
  • 8.4. Manufacturing
    • 8.4.1. Downstream
      • 8.4.1.1. Chromatography
      • 8.4.1.2. Filtration
    • 8.4.2. Upstream
      • 8.4.2.1. Single Use
      • 8.4.2.2. Stainless Steel

9. Biologics Outsourcing Market, by Therapeutic Area

  • 9.1. Cell Therapy
    • 9.1.1. Allogeneic
    • 9.1.2. Autologous
  • 9.2. Gene Therapy
    • 9.2.1. Non Viral
    • 9.2.2. Viral Vector
  • 9.3. Monoclonal Antibodies
  • 9.4. Vaccines
    • 9.4.1. Prophylactic
      • 9.4.1.1. Bacterial
      • 9.4.1.2. Viral
    • 9.4.2. Therapeutic

10. Biologics Outsourcing Market, by Process Stage

  • 10.1. Clinical
    • 10.1.1. Phase I
    • 10.1.2. Phase II
    • 10.1.3. Phase III
  • 10.2. Commercial
  • 10.3. Research

11. Biologics Outsourcing Market, by End User

  • 11.1. Biotech Companies
  • 11.2. Pharmaceutical Companies
  • 11.3. Research Institutes

12. Biologics Outsourcing Market, by Outsourcing Model

  • 12.1. CDMO
  • 12.2. CMO
  • 12.3. CRO

13. Biologics Outsourcing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Biologics Outsourcing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Biologics Outsourcing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Biologics Outsourcing Market

17. China Biologics Outsourcing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AGC Biologics, Inc.
  • 18.6. Almac Group Limited
  • 18.7. BioReliance Corporation
  • 18.8. Boehringer Ingelheim International GmbH
  • 18.9. Catalent, Inc.
  • 18.10. Charles River Laboratories International, Inc.
  • 18.11. Cognate BioServices, Inc.
  • 18.12. Eurofins Scientific SE
  • 18.13. Evotec SE
  • 18.14. Fujifilm Diosynth Biotechnologies, Inc.
  • 18.15. ICON plc
  • 18.16. IQVIA Holdings Inc.
  • 18.17. KBI Biopharma, Inc.
  • 18.18. Labcorp Drug Development, Inc.
  • 18.19. Lonza Group AG
  • 18.20. Medpace Holdings, Inc.
  • 18.21. Parexel International Corporation
  • 18.22. PPD, Inc.
  • 18.23. PRA Health Sciences, Inc.
  • 18.24. Recipharm AB
  • 18.25. Samsung Biologics Co., Ltd.
  • 18.26. Sartorius Stedim Biotech S.A.
  • 18.27. Syngene International Limited
  • 18.28. Thermo Fisher Scientific Inc.
  • 18.29. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOLOGICS OUTSOURCING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIOLOGICS OUTSOURCING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PROCESS STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY OUTSOURCING MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY ANALYTICAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY ANALYTICAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY ANALYTICAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY FILL FINISH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY FILL FINISH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY FILL FINISH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY DOWNSTREAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY DOWNSTREAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY DOWNSTREAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY FILTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY FILTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY FILTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY UPSTREAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY UPSTREAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY UPSTREAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SINGLE USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SINGLE USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SINGLE USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY STAINLESS STEEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY STAINLESS STEEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY STAINLESS STEEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY NON VIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY NON VIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY NON VIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PROPHYLACTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PROPHYLACTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY VIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY VIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CLINICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CLINICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY OUTSOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CDMO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CDMO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CDMO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CMO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CMO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CMO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CRO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CRO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CRO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY OUTSOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY OUTSOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA BIOLOGICS OUTSOURCING MARKET SIZE, BY OUTSOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY OUTSOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE BIOLOGICS OUTSOURCING MARKET SIZE, BY MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE BIOLOGICS OUTSOURCING MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE BIOLOGICS OUTSOURCING MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE BIOLOGICS OUTSOURCING MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE BIOLOGICS OUTSOURCING MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE BIOLOGICS OUTSOURCING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE BIOLOGICS OUTSOURCING MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE BIOLOGICS OUTSOURCING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE BIOLOGICS OUTSOURCING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE BIOLOGICS OUTSOURCING MARKET SIZE, BY OUTSOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST BIOLOGICS OUTSOURCING MARKET SIZE, BY MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST BIOLOGICS OUTSOURCING MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST BIOLOGICS OUTSOURCING MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST BIOLOGICS OUTSOURCING MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST BIOLOGICS OUTSOURCING MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST BIOLOGICS OUTSOURCING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST BIOLOGICS OUTSOURCING MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST BIOLOGICS OUTSOURCING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST BIOLOGICS OUTSOURCING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST BIOLOGICS OUTSOURCING MARKET SIZE, BY OUTSOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY OUTSOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY OUTSOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN BIOLOGICS OUTSOURCING MARKET SIZE, BY MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN BIOLOGICS OUTSOURCING MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN BIOLOGICS OUTSOURCING MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN BIOLOGICS OUTSOURCING MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN BIOLOGICS OUTSOURCING MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN BIOLOGICS OUTSOURCING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN BIOLOGICS OUTSOURCING MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN BIOLOGICS OUTSOURCING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN BIOLOGICS OUTSOURCING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN BIOLOGICS OUTSOURCING MARKET SIZE, BY OUTSOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 245. GCC BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 246. GCC BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. GCC BIOLOGICS OUTSOURCING MARKET SIZE, BY MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 248. GCC BIOLOGICS OUTSOURCING MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 249. GCC BIOLOGICS OUTSOURCING MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 250. GCC BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 251. GCC BIOLOGICS OUTSOURCING MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 252. GCC BIOLOGICS OUTSOURCING MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 253. GCC BIOLOGICS OUTSOURCING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 254. GCC BIOLOGICS OUTSOURCING MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 255. GCC BIOLOGICS OUTSOURCING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 256. GCC BIOLOGICS OUTSOURCING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 257. GCC BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. GCC BIOLOGICS OUTSOURCING MARKET SIZE, BY OUTSOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION BIOLOGICS OUTSOURCING MARKET SIZE, BY MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION BIOLOGICS OUTSOURCING MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION BIOLOGICS OUTSOURCING MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION BIOLOGICS OUTSOURCING MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION BIOLOGICS OUTSOURCING MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION BIOLOGICS OUTSOURCING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION BIOLOGICS OUTSOURCING MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION BIOLOGICS OUTSOURCING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION BIOLOGICS OUTSOURCING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION BIOLOGICS OUTSOURCING MARKET SIZE, BY OUTSOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS BIOLOGICS OUTSOURCING MARKET SIZE, BY MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS BIOLOGICS OUTSOURCING MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS BIOLOGICS OUTSOURCING MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS BIOLOGICS OUTSOURCING MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS BIOLOGICS OUTSOURCING MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS BIOLOGICS OUTSOURCING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS BIOLOGICS OUTSOURCING MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS BIOLOGICS OUTSOURCING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS BIOLOGICS OUTSOURCING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS BIOLOGICS OUTSOURCING MARKET SIZE, BY OUTSOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 287. G7 BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 288. G7 BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. G7 BIOLOGICS OUTSOURCING MARKET SIZE, BY MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 290. G7 BIOLOGICS OUTSOURCING MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 291. G7 BIOLOGICS OUTSOURCING MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 292. G7 BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 293. G7 BIOLOGICS OUTSOURCING MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 294. G7 BIOLOGICS OUTSOURCING MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 295. G7 BIOLOGICS OUTSOURCING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 296. G7 BIOLOGICS OUTSOURCING MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 297. G7 BIOLOGICS OUTSOURCING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 298. G7 BIOLOGICS OUTSOURCING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 299. G7 BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 300. G7 BIOLOGICS OUTSOURCING MARKET SIZE, BY OUTSOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 301. NATO BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 302. NATO BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. NATO BIOLOGICS OUTSOURCING MARKET SIZE, BY MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 304. NATO BIOLOGICS OUTSOURCING MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 305. NATO BIOLOGICS OUTSOURCING MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 306. NATO BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 307. NATO BIOLOGICS OUTSOURCING MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 308. NATO BIOLOGICS OUTSOURCING MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 309. NATO BIOLOGICS OUTSOURCING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 310. NATO BIOLOGICS OUTSOURCING MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 311. NATO BIOLOGICS OUTSOURCING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 312. NATO BIOLOGICS OUTSOURCING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 313. NATO BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 314. NATO BIOLOGICS OUTSOURCING MARKET SIZE, BY OUTSOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 315. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 327. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 328. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 329. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY OUTSOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 330. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 331. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 332. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 333. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 334. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY UPSTREAM, 20